Klow80 Blend (TB-500 / BPC-157 / GHK-Cu / KPV)
An 80mg research peptide blend combining TB-500 (10mg), BPC-157 (10mg), GHK-Cu (50mg), and KPV (10mg) — integrating potent anti-inflammatory action with tissue repair, collagen synthesis, and anti-aging gene modulation for comprehensive regeneration. The name KLOW derives from KPV + GLOW.
Overview
The Klow80 Blend adds a critical fourth dimension to the Glow Blend: targeted anti-inflammatory control. KPV (Lys-Pro-Val) is the C-terminal tripeptide fragment of alpha-melanocyte-stimulating hormone (α-MSH) that retains the full anti-inflammatory potency of the parent hormone without its melanogenic (skin-darkening) effects.
- KPV inhibits NF-κB — the master inflammatory transcription factor — reducing pro-inflammatory cytokine production (TNF-α, IL-6, IL-1β), creating a more permissive environment for repair
- KPV reduces injection site reactions — a practical benefit over the base Glow Blend, as local inflammation at SC injection sites is a common complaint
- KPV supports gut health — α-MSH fragments have demonstrated protective effects on intestinal epithelium, complementing BPC-157's gut-healing properties
- KPV has antimicrobial properties — direct antimicrobial activity against multiple pathogens, adding infection resistance to wound healing
This creates a comprehensive healing environment: KPV suppresses excessive inflammation → TB-500 migrates repair cells to target sites → BPC-157 upregulates growth factors and protects tissue → GHK-Cu programs cells for youthful gene expression and collagen production.
Mechanism of Action
The Anti-Inflammatory Layer
KPV acts primarily through inhibition of the NF-κB signaling pathway. It enters cells and prevents activation of the IKK complex, blocking nuclear translocation of NF-κB and subsequent transcription of pro-inflammatory mediators. This mechanism is distinct from corticosteroids and NSAIDs, operating at a different point in the inflammatory cascade.
The anti-inflammatory action of KPV:
- Inhibits NF-κB nuclear translocation — preventing transcription of TNF-α, IL-6, IL-1β, and other pro-inflammatory cytokines that can impair tissue repair when chronically elevated
- Reduces local inflammation — at injection sites and in target tissues, creating optimal conditions for the repair peptides to function
- Supports intestinal barrier integrity — α-MSH fragments protect intestinal epithelial cells from inflammatory damage, complementing BPC-157's gut-protective effects
- Provides antimicrobial defense — KPV has demonstrated direct antimicrobial activity, reducing infection risk in wound healing contexts
Repair Peptide Synergies (TB-500 + BPC-157 + GHK-Cu)
The three repair peptides operate through complementary mechanisms:
- TB-500: Cell migration through actin sequestration, angiogenesis via endothelial cell mobilization (Grant et al., 1999)
- BPC-157: VEGFR2-mediated vascular growth, growth factor upregulation, gut-skin axis support, cytoprotection (Chang et al., 2014)
- GHK-Cu: Gene expression reprogramming (32% of human genome), collagen/elastin synthesis, copper-dependent antioxidant defense (Pickart & Margolina, 2018)
The KPV / BPC-157 Synergy
The interaction between KPV and BPC-157 deserves special attention. Both peptides have independent gut-protective and anti-inflammatory properties, but they operate through different mechanisms — KPV via NF-κB inhibition and BPC-157 via VEGFR2-mediated vascular repair and cytoprotection. Their combination may provide more comprehensive tissue protection than either alone, particularly in contexts involving both inflammation and tissue damage. KPV's ability to reduce local inflammation also means the angiogenic and repair actions of BPC-157 and TB-500 occur in a less hostile tissue environment.
Reconstitution Calculator
Research
The compounded blend (no direct evidence)
Klow80 is a compounded, non-FDA-approved multi-peptide product pairing TB-500 (a thymosin beta-4 fragment), BPC-157, GHK-Cu and KPV on the rationale that combining regenerative, angiogenic, anti-inflammatory and collagen-stimulating peptides yields broad tissue-repair effects. No clinical trials have evaluated the blend itself; all human and preclinical evidence derives from the individual components, and the safety/efficacy of the fixed combination is unestablished.
- No published trials of the combined blend
- Rationale rests on complementary repair mechanisms of four peptides
- Component doses, interactions and long-term safety are uncharacterized
Thymosin beta-4 / TB-500
Thymosin beta-4 is an actin-sequestering peptide that promotes cell migration, angiogenesis and tissue repair; TB-500 is a related synthetic fragment. Human development has focused on cardiac repair (RGN-352, now succeeded by newer recombinant programs) and ophthalmic use (RGN-259 for dry eye and neurotrophic keratopathy). The 2025 STEMI RCT provided the first randomized human efficacy signal, strongest when given early after reperfusion.
- Actin-sequestering peptide driving migration, angiogenesis and repair
- First human STEMI RCT showed benefit in early-treated subgroup
- Ophthalmic ARISE dry-eye program showed safety but mixed primary-endpoint results
BPC-157, GHK-Cu and KPV
BPC-157 ('body protection compound') is a stable gastric pentadecapeptide with extensive preclinical evidence for tendon, muscle, gut and vascular healing but only nascent human trials, and it is an unapproved drug flagged by the FDA/DoD. GHK-Cu, a copper-binding tripeptide, has the most human dermatologic data of the four, stimulating collagen synthesis and wound healing. KPV is the C-terminal tripeptide of alpha-MSH with potent anti-inflammatory activity in preclinical colitis and wound models.
- BPC-157: broad preclinical healing effects; human trials only now beginning; unapproved
- GHK-Cu: collagen-stimulating copper peptide with dermatologic clinical use
- KPV: anti-inflammatory alpha-MSH fragment studied preclinically for IBD and wound healing
Safety Profile
All four components have favorable preclinical safety profiles. KPV is a fragment of the endogenous hormone α-MSH and retains anti-inflammatory activity without the melanogenic effects of the full hormone. TB-500 has extensive veterinary safety data. BPC-157 has a wide therapeutic window. GHK-Cu is endogenous. KPV does not affect GH, cortisol, ACTH, or prolactin, making it a low-risk addition to the blend. Human clinical data for the four-component blend does not exist.
Pharmacokinetic Profile
Quick Start
- Route
- Subcutaneous injection
Research Indications
Intended (Compounded) Uses of the Blend
The blend combines TB-500 (thymosin beta-4 fragment), BPC-157, GHK-Cu and KPV to target soft-tissue, tendon, gut and skin repair; no clinical trials evaluate the combination itself.
KPV (an alpha-MSH C-terminal tripeptide) and BPC-157 are included for anti-inflammatory and gastrointestinal-protective actions in preclinical models.
GHK-Cu contributes collagen-stimulating, wound-healing and antioxidant effects documented mainly in dermatologic/cosmetic studies.
Component Evidence (individual peptides)
Parent peptide thymosin beta-4 has reached human trials for cardiac injury and dry eye; TB-500 is a related fragment used in research.
Extensive preclinical healing data; first controlled human trials only now beginning. Unapproved and flagged by regulators.
Copper tripeptide with the most human (dermatologic) data of the four components.
Research Protocols
subcutaneous Injection
Administered via subcutaneous injection.
| Goal | Dose | Frequency | Duration |
|---|---|---|---|
| General Research Protocol | See literature | Daily | 4-6 weeks(Route: Subcutaneous Injection) |
| Cycling | See literature | Daily | 4-6 weeks(Route: Subcutaneous Injection) |
Interactions
Peptide Interactions
- GH amplifies angiogenesis — IGF-1 is a potent angiogenic factor that works alongside the vascular growth promoted by TB-500, BPC-157, and GHK-Cu - BPC-157 upregulates GH receptors — BPC-157 increases growth hormone receptor expression on fibroblasts ([Chang et al.
The three repair peptides operate through the same complementary mechanisms described in the Glow Blend: - TB-500: Cell migration through actin sequestration, angiogenesis via endothelial cell mobilization ([Grant et al.
- GH amplifies angiogenesis — IGF-1 is a potent angiogenic factor that works alongside the vascular growth promoted by TB-500, BPC-157, and GHK-Cu - BPC-157 upregulates GH receptors — BPC-157 increases growth hormone receptor expression on fibroblasts ([Chang et al.
- GH amplifies angiogenesis — IGF-1 is a potent angiogenic factor that works alongside the vascular growth promoted by TB-500, BPC-157, and GHK-Cu - BPC-157 upregulates GH receptors — BPC-157 increases growth hormone receptor expression on fibroblasts ([Chang et al.
BPC-157 upregulates growth hormone receptor density on fibroblasts and other repair cells, effectively increasing the tissue-level sensitivity to the GH released by Ipamorelin.
- GH amplifies angiogenesis — IGF-1 is a potent angiogenic factor that works alongside the vascular growth promoted by TB-500, BPC-157, and GHK-Cu - BPC-157 upregulates GH receptors — BPC-157 increases growth hormone receptor expression on fibroblasts ([Chang et al.
Quality Indicators
What to look for
- Multiple peer-reviewed studies available
Frequently Asked Questions
References (10)
- [9]Pickart L et al GHK-Cu may prevent oxidative stress in skin by regulating copper and modifying expression of numerous antioxidant genes Cosmetics (2014)
- [1]
- [8]Pickart L & Margolina A Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data Int J Mol Sci (2018)
- [6]
- [2]Chang CH et al Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts Molecules (2014)
- [3]Grant DS et al Thymosin beta4 promotes angiogenesis in the chick chorioallantoic membrane Angiogenesis (1999)
- [10]Canapp SO et al The effect of topical tripeptide-copper complex on healing of ischemic open wounds Vet Surg (2003)
- [8]Zhang Y, Dong Q, Bian X, et al.; Yin D, Dou K Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion Cardiovascular Research (2025)
→ First human RCT of recombinant thymosin beta-4 (the parent of TB-500) in STEMI (96 patients): the overall infarct-size difference was non-significant, but patients treated within 8 h of PCI had a significant reduction in infarct size versus placebo.
- [9]Pickart L, Vasquez-Soltero JM, Margolina A GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration BioMed Research International (2015)
→ Reviews evidence that the copper tripeptide GHK-Cu stimulates collagen/GAG synthesis, wound healing and antioxidant defenses and modulates a broad set of skin-regeneration genes, underpinning its cosmetic and repair uses.
- [10]BPC 157 for Acute Hamstring Muscle Strain Repair (Phase 2 randomized trial registration) ClinicalTrials.gov (2025)
→ Registered randomized, double-blind, placebo-controlled Phase 2 trial testing BPC-157 versus placebo (14 days) plus rehabilitation for acute grade II hamstring strain, with return-to-sport and MRI injury-volume co-primary endpoints; among the first controlled human evaluations of BPC-157.
Klotho
**Klotho** is a type I transmembrane protein originally identified in 1997 as an aging-suppressor gene in mice, where its disruption caused a syndrome resemblin
KLOW Protocol
KLOW is a blended protocol that extends the GLOW stack by adding KPV. It combines four peptides: BPC-157, TB-500 (thymosin beta-4 fragment), GHK-Cu (copper trip